Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

VRCA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Verrica Pharmaceuticals Inc.NASDAQ: VRCA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 10.65M shares rose 12.3% year over year, behind the +57.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +46.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +12.3% toward the trailing-twelve-month pace of +57.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
10.65M+0.0% QoQ
Last fiscal yearDec 2025
10.65M+105.6% YoY
LTMMar 2026
10.07M+57.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.3%——
1 year+105.6%——
3-year CAGR+46.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
10.65M USD
Year-over-year change
+105.6%
4-year CAGR
+40.9%

Weighted Avg Shares vs competitors

How VRCA compares with its peers on the latest reported figures

  • VRCA's LTM Mar 2026 weighted avg shares of 10.07M shares is the lowest of the 5 companies compared; the peer median is 26.78M shares.
  • Its year-over-year change of +57.7% is the 2nd highest of 5, against a peer median of +6.3%.
  • Over three fiscal years its annual growth of +46.1% compares with a peer median of +41.1%.
VRCA Competitors Peer median
Weighted Avg Shares for VRCA and competitors
Company Period LTM YoY 3-year CAGR
SABSSAB Biotherapeutics, Inc.LTM Jun 202640.82M +340.0%+64.3%
ANTXAN2 Therapeutics, Inc.LTM Mar 202631.18M +4.3%+25.4%
BOLDBoundless Bio, Inc.LTM Mar 202622.38M +7.1%+0.2%
QTTBQ32 Bio Inc.LTM Mar 202612.77M +5.5%+56.8%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 202610.07M +57.7%+46.1%
Peer median (excluding VRCA) 26.78M+6.3%+41.1%

Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12M9.03M5.12M7.57M35.58M
Cost of Revenue472K725K746K2.74M3.44M
Gross Profit11.53M8.31M4.38M4.83M32.14M
Gross Margin96.1%92.0%85.4%63.8%90.3%
Research & Development15.93M12.2M20.3M11.84M8.86M
Selling, General & Admin26.98M17.41M47.31M58.82M35.22M
Operating Expenses42.44M29.6M70.14M70.75M44.08M
Depreciation & Amortization472K718K836K1.27M781K
EBITDA(30.31M)(21.6M)(62.2M)(65.9M)(9.36M)
EBITDA Margin-252.6%-239.1%-1213.8%-871.0%-26.3%
Operating Income(30.91M)(21.3M)(65.76M)(65.92M)(11.94M)
Operating Margin-257.6%-235.8%-1283.4%-871.3%-33.6%
Interest Income123K476K2.74M1.42M929K
Interest Expense4.3M2.17M3.96M9.41M7.74M
Other Income / Expenses(4.17M)(3.19M)(1.24M)(10.66M)(5.95M)
Income Before Tax(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Pre-Tax Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
Income Tax Expense00000
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Net Margin-292.3%-271.1%-1307.5%-1012.1%-50.3%
EPS (Basic)(12.97)(7.17)(14.78)(14.78)(1.68)
EPS (Diluted)(12.97)(7.17)(14.78)(14.78)(1.68)
Weighted Avg Shares2.7M3.42M4.53M5.18M10.65M
Weighted Avg Shares (Diluted)2.7M3.42M4.53M5.18M10.65M

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Intrinsic Alpha fair value

Locked

Current Price

$3.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.